In Vivo and Computational Studies on Sitagliptin’s Neuroprotective Role in Type 2 Diabetes Mellitus: Implications for Alzheimer’s Disease
Vasudevan Mani, Minhajul Arfeen · 2024
Read In Vivo and Computational Studies on Sitagliptin’s Neuroprotective Role in Type 2 Diabetes Mellitus: Implications for Alzheimer’s Disease by Vasudevan Mani, Minhajul Arfeen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11674309.txt.
Description
Vasudevan Mani and Minhajul Arfeen test whether a common diabetes drug can also shield the brain. Sitagliptin manages blood sugar in type 2 diabetes, a condition that raises the risk of Alzheimer's disease. In rats made diabetic with two chemicals, the team measured brain enzymes tied to Alzheimer's, plus inflammation, oxidative stress, and cell death markers. Computer docking studies checked how the drug might grip those targets.
The drug lowered the Alzheimer's-linked enzymes and the diabetes enzyme it is known for, cut inflammation signals, and eased oxidative stress. It also tilted cell survival markers toward life, lowered blood sugar, and improved insulin. Docking scores matched those of known binders for five targets. The authors present sitagliptin as a candidate worth pursuing against diabetes-linked brain decline.
Catalog record
| CREATOR | Vasudevan Mani, Minhajul Arfeen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |